Language | English |
---|---|
Pages | 663-640 |
Journal | The Lancet |
Volume | 379 |
Issue number | 9816 |
DOIs | |
Publication status | Published - 2012 |
Cite this
}
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. / Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Kauria, Karine; Van Dooren, Veerie; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Gunz, Georg; Hyuk Sohn, Joo; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymur; Pusztai, Lajos.
In: The Lancet, Vol. 379, No. 9816, 2012, p. 663-640.Research output: Contribution to journal › Article
TY - JOUR
T1 - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
AU - Baselga, Jose
AU - Bradbury, Ian
AU - Eidtmann, Holger
AU - Di Cosimo, Serena
AU - de Azambuja, Evandro
AU - Aura, Claudia
AU - Gomez, Henry
AU - Dinh, Phuong
AU - Kauria, Karine
AU - Van Dooren, Veerie
AU - Aktan, Gursel
AU - Goldhirsch, Aron
AU - Chang, Tsai-Wang
AU - Horvath, Zsolt
AU - Coccia-Portugal, Maria
AU - Domont, Julien
AU - Tseng, Ling-Min
AU - Gunz, Georg
AU - Hyuk Sohn, Joo
AU - Semiglazov, Vladimir
AU - Lerzo, Guillermo
AU - Palacova, Marketa
AU - Probachai, Volodymur
AU - Pusztai, Lajos
PY - 2012
Y1 - 2012
U2 - 10.1016/S0140-6736(11)61847-3
DO - 10.1016/S0140-6736(11)61847-3
M3 - Article
VL - 379
SP - 663
EP - 640
JO - Lancet
T2 - Lancet
JF - Lancet
SN - 0140-6736
IS - 9816
ER -